"In clinical news, leronlimab is showing early signs of activity in metastatic colorectal cancer. Preliminary data presented at AACR 2026 point to both clinical responses and biomarker engagement, suggesting the therapy may have potential in a difficult-to-treat population. While still early-stage, these findings add to the growing interest in immune-modulating approaches beyond traditional checkpoint inhibitors."
https://www.biopharminternational.com/view/th...power-move